Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7784820 | 0.88 | HTT (0.41) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL31531584 | 0.88 | CYP2D6 (0.47) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL8429788 | 0.88 | CYP2D6 (0.47) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL1145124 | 0.86 | ALDH1A1 (0.49) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL23115658 | 0.84 | HTT (0.38) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL29617504 | 0.84 | HTT (0.38) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL18398219 | 0.84 | HTT (0.38) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL11141869 | 0.84 | HTT (0.38) | HTTPOLBGABRA1GABRB2MAPT | |
| SCHEMBL19701762 | 0.81 | MAPT (0.46) | POLBMAPTL3MBTL1GAATDP1 | |
| SCHEMBL21633060 | 0.80 | MAPT (0.38) | HTTPOLBGABRA1GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417125-B1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-09-09 | — | — | EP | claimed |
| US-8772280-B2 | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | claimed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | claimed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| CN-1157386-C | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | ղɭҩҵ����˾ | 2004-07-14 | — | — | CN | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| CN-1295566-A | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | JANSSEN PHARMACEUTICA NV (BE) | 2001-05-16 | — | — | CN | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| US-11760868-B2 | Preparation method for a flame retardant polystyrene | Useon (Nanjing) Extrusion Machinery Co., Ltd. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230151199-A1 | PREPARATION METHOD FOR A FLAME RETARDANT POLYSTYRENE | USEON TECHNOLOGY LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| CN-113896822-B | Preparation method of high-efficiency flame-retardant polystyrene by applying bromine flame retardant containing active functional group | 江苏越升科技股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114907267-A | Pharmaceutical composition for resisting tumor | 中国科学院上海药物研究所 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022166990-A1 | ANTI-TUMOR PHARMACEUTICAL COMBINATION | 中国科学院上海药物研究所 | 2022-08-11 | — | — | WO | disclosed |
| US-4418209-A | ANTIULCER, ANTIARRYTHMIC, ANTIDIARRHEAL, ANTISPASMODIC, ANTIPARASITIC, AND ANTISECRETORY AGENTS | WILLIAM H. RORER, INC. (US) | 1983-11-29 | — | — | US | disclosed |
| US-4326075-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4203920-A | ANTIDIARRHEAL | WILLIAM H. RORER, INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4060635-A | Amidinoureas for treating diarrhea | WILLIAM H. RORER, INC. (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | HTT 1949/4885POLB 2618/4885GABRA1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.